DIRS.INFO The most relevant business & tech news

☆ Ozempic, Mounjaro and hundreds of other drugs become even more expensive in 2024
▼ + stars: | 2024-02-15 | by ( Tami Luhby | ) edition.cnn.com time to read: +8 min

Novo Nordisk boosted the list price of Ozempic by 3.5% to $969 for a four-week supply. Eli Lilly last month raised the list price of Mounjaro by 4.5% to $1,069 for a four-week supply. However, they may have to pay the list price if they are uninsured or have not yet hit their annual deductible. Former President Donald Trump, who is running for election again, also unveiled several proposals and issued executive orders aimed at lowering drug costs during his administration. Another factor is the recent policies that penalize pharmaceutical manufacturers for raising list prices faster than inflation.

Persons: Drugmakers, Eli Lilly, Eli Lilly’s Zepbound, Ozempic, Eli Lily, Marlene Foss, Foss, “, ”, Mark Rapp, Rapp, ’ ”, Mark Rapp's, grandkids, ” Rapp, Joe Biden’s, Donald Trump, We’ve, Antonio Ciaccia, we’ve Organizations: New, New York CNN, Ozempic, Novo Nordisk, CNN, Food and Drug Administration, Nordisk’s, Mounjaro, Medicare, ”, White House Locations: New York, Portugal, Doylestown , Pennsylvania, Italy, Mansfield , Ohio, Ohio, Idaho

☆ Trial confirms heart benefits of Wegovy, but is weight loss responsible – or something else?
▼ + stars: | 2023-11-11 | by ( Meg Tirrell | ) edition.cnn.com time to read: +9 min

To cardiologist Dr. Steven Nissen of the Cleveland Clinic, who wasn’t involved in the trial but is leading a similar one of tirzepatide, those effects are all evidence of the benefits of weight loss. Tirzepatide has shown greater levels of weight loss than semaglutide in clinical trials, leading many, including Nissen, to hope it will show even stronger cardiovascular benefits. Importantly, participants didn’t have a history of diabetes; a previous trial had shown that treating people with diabetes with a GLP-1 drug, Ozempic, reduced their cardiovascular risk. The Wegovy trial showed that 569 of 8,803 people taking the drug had a heart attack or stroke or died from heart-related causes, or 6.5%. The amount of weight loss seen in the trial, 9.4%, was less than in other studies of Wegovy, which showed average weight loss closer to 15%.

Persons: Ania Jastreboff, Wegovy, Dr, Amit Khera, National Institutes of Health’s Dr, Tiffany M, Powell, Wiley, Eli Lilly, Steven Nissen, wasn’t, ” Nissen, “, Tirzepatide, Nissen, Michael Lincoff, Lincoff, ”, Jastreboff, Sanjay Gupta, hadn’t, “ semaglutide Organizations: CNN, Nordisk’s Wegovy, American Heart Association, Yale Obesity Research Center, University of Texas Southwestern Medical Center Dallas, National Institutes of Health’s, New England, of Medicine, US Food and Drug, Cleveland Clinic, Novo Nordisk, Cleveland, CNN Health Locations: Philadelphia, Powell

☆ Lilly to buy Versanis for up to $1.93 billion to boost obesity drug portfolio
▼ + stars: | 2023-07-14 | by ( Reuters Staff | ) www.reuters.com time to read: 1 min

FILE PHOTO: Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. REUTERS/Mike Blake/File Photo(Reuters) -Eli Lilly and Co said on Friday it will acquire privately held drug developer Versanis for up to $1.93 billion, in a bid to boost its portfolio of obesity drugs. Under the terms of the agreement, Versanis shareholders could receive $1.93 billion in cash, which includes an upfront payment and subsequent payments upon achievement of certain development and sales milestones. Versanis’s lead drug, bimagrumab, is being evaluated in a mid-stage trial alone as well as in combination with Novo Nordisk’s Wegovy or semaglutide in adults who are overweight or obese.

Persons: Eli Lilly, Mike Blake Organizations: REUTERS, Nordisk’s Locations: San Diego , California, U.S

☆ Daily pill from Eli Lilly leads to 15% weight loss in midstage study, rivaling Wegovy results without the shot
▼ + stars: | 2023-06-23 | by ( Meg Tirrell | ) edition.cnn.com time to read: +4 min

Currently approved medicines for weight loss like Novo Nordisk’s Wegovy are given as once-weekly injections. Novo Nordisk’s Ozempic, which contains the same key ingredient as Wegovy, called semaglutide, and Lilly’s Mounjaro are both approved for Type 2 diabetes but used off-label for weight loss. Weight loss at 36 weeks ranged from 9.4% to 14.7%, compared with 2.3% on placebo, the results showed. Lilly’s is just one of a crop of experimental weight loss drugs seeking to join blockbusters like Wegovy on the market. Novo Nordisk reported results last month showing that a pill version of semaglutide yielded 15% weight loss over 68 weeks, similar to Wegovy’s results.

Persons: Eli Lilly’s, what’s, Lilly, Lilly’s, ”, Nadia Ahmad, orforglipron, “ you’re, Dr, Sean Wharton, White, Ahmad, it’s, Sanjay Gupta, semaglutide Organizations: CNN, New England, of Medicine, American Diabetes Association, Nordisk’s, Nordisk’s Ozempic, Wharton Medical Clinic, CNN Health, Novo Nordisk, Pfizer Locations: San Diego

☆ Big Pharma will muscle in on obesity gold rush
▼ + stars: | 2022-11-28 | by ( Aimee Donnellan | ) www.reuters.com time to read: +4 min

LONDON, Nov 28 (Reuters Breakingviews) - Obesity drugs are a modern day gold rush for drugmakers. By then, the obesity market could total $50 billion, according to Morgan Stanley. But a plausible 50% price cut would lower annual sales to $25 billion. Reuters GraphicsFollow @aimeedonnellan on TwitterCONTEXT NEWSSales of Novo Nordisk’s obesity drugs Wegovy and Saxenda reached nearly $1.2 billion in 2021, up 50% versus the previous year. Morgan Stanley analysts expect the obesity market to grow to $50 billion in annual sales by 2030.

Search resuls for: "Nordisk’s Wegovy"

5 mentions found